Investigation of Optimal Prostate Biopsy Schemes for Chinese Patients with Different Clinical Characteristics
Investigation of Optimal Prostate Biopsy Schemes for Chinese Patients with Different Clinical Characteristics
复制标题
中国不同临床特征患者最佳前列腺活检方案的探讨
DOI：
10.1159/000341694
复制
发表时间：
2012-01-01
影响因子：
1.6
通讯作者：
Gao, Xin
中科院分区：
文献类型：
--
作者：
Chen, Ming-Kun;Luo, Yun;Gao, Xin
Purpose: To investigate the optimal schemes of prostate biopsy according to prostate volume (PV), age and transrectal ultrasound (TRUS) status in Chinese men. Methods: 923 consecutive patients who underwent initial TRUS-guided systematic 12-core prostate biopsy (12PBx) were enrolled in this study. The 12PBx was obtained by overlapping of conventional sextant, lateral base, mid-gland of peripheral zone and apex. Each sample was individually marked and inked before fixation. Patients were divided into 8 subgroups on the basis of independent risk factors investigated using logistic regression model. Subsequently, 12PBx was defined as self-control for the analysis of biopsy schemes (6-, 8- and 10PBx) on individual core basis. The prostate cancer detection rates (CDRs) of 6-, 8-, 10- and 12PBx were compared for each individual subgroup. Results: The 12PBx detected 253 (27.4%) cases of prostate cancer (PCa), of which 67.2, 47.1 and 61.3% were located in the base, mid-gland and apex, respectively. Multivariate analysis indicated that age, TRUS status and PV were independent risk factors for PCa detection. CDR increased with increasing biopsy cores. However, for patients with age >= 65 years, positive TRUS and PV = 65 years, negative TRUS and PV = 65 years, positive TRUS and PV >= 38.5 cm(3), 10PBx was as effective as 12PBx in detecting PCa (27.8, 27.5 vs. 28.9, 29.3%, respectively). Conclusion: Age, TRUS status and PV were independent risk factors for PCa detection. Traditional sextant biopsy is not recommended. 8-, 10-, or 12PBx as an individual biopsy scheme might be adopted according to these risk factors for Chinese patients. Copyright (c) 2012 S. Karger AG, Basel
